Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John V Amerena

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|June 12, 2015
Rivaroxaban in the Prevention of Stroke and Systemic Embolism in Patients with Non-Valvular Atrial Fibrillation: Clinical Implications of the ROCKET AF Trial and Its SubanalysesRyan J Spencer, John V Amerena
Heart, Lung & Circulation|October 11, 2020
Combating Inflammation in Cardiovascular DiseaseAnver M Sethwala, Ian Goh, John V Amerena
The Medical Journal of Australia|November 5, 2013
Update on the management of atrial fibrillationJohn V Amerena, Tomos E Walters, Sam Mirzaee, et al.
The Medical Journal of Australia|June 19, 2008
Invasive management and late clinical outcomes in contemporary Australian management of acute coronary syndromes: observations from the ACACIA registryDerek P Chew, John V Amerena, Steve G Coverdale, et al.
The Medical Journal of Australia|November 17, 2009
Treatment disparities and effect on late mortality in patients with diabetes presenting with acute myocardial infarction: observations from the ACACIA registryJoseph Hung, David B Brieger, John V Amerena, et al.
Circulation|June 18, 2013
The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) StudyStuart J Connolly, Lars Wallentin, Michael D Ezekowitz, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|June 12, 2015
Rivaroxaban in the Prevention of Stroke and Systemic Embolism in Patients with Non-Valvular Atrial Fibrillation: Clinical Implications of the ROCKET AF Trial and Its SubanalysesRyan J Spencer, John V Amerena
Heart, Lung & Circulation|October 11, 2020
Combating Inflammation in Cardiovascular DiseaseAnver M Sethwala, Ian Goh, John V Amerena
The Medical Journal of Australia|November 5, 2013
Update on the management of atrial fibrillationJohn V Amerena, Tomos E Walters, Sam Mirzaee, et al.
The Medical Journal of Australia|June 19, 2008
Invasive management and late clinical outcomes in contemporary Australian management of acute coronary syndromes: observations from the ACACIA registryDerek P Chew, John V Amerena, Steve G Coverdale, et al.
The Medical Journal of Australia|November 17, 2009
Treatment disparities and effect on late mortality in patients with diabetes presenting with acute myocardial infarction: observations from the ACACIA registryJoseph Hung, David B Brieger, John V Amerena, et al.
Circulation|June 18, 2013
The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) StudyStuart J Connolly, Lars Wallentin, Michael D Ezekowitz, et al.
Pageof 1